Screening method of TTR (transthyretin) small-molecule inhibitors

A technology of small molecule inhibitors and screening methods, which is applied in the fields of instruments, computing, and electronic digital data processing, etc., can solve problems such as unclear causes of aggregation, metabolic disorders, and instability, so as to save time and research funds and improve reliability. performance, and the effect of improving the screening speed

CN103425859AInactive Publication Date: 2013-12-04BEIJING UNIV OF CHEM TECH
0 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2013-12-04
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention aims to establish an efficient, fast and reliable screening method of TTR (transthyretin) small-molecule inhibitors, overcomes the defects of the prior art and is applicable to design of medicines for amyloidosis caused by TTR fibrosis. A small-molecule database is screened and predicted by means of 3D-QSAR (3-dimensional quantitative structure activity relationship), molecular docking, pharmacophore models and the like; small molecules capable of serving as lead compounds are determined preliminarily; further cell screening is performed. The screening method is fast and efficient; a plurality of drug screening and design methods based on receptors and ligands are applied; accordingly, reliability of screening results is improved greatly. Cell levels are subjected to biological screening by lead compounds obtained by screening, so that screening speed is higher and development and search cycle of novel inhibitors is shortened.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a method for drug screening and prediction, in particular to a method for drug screening and prediction of a small molecule inhibitor with TTR protein as a receptor. Background technique

[0002] Thyroid binding prealbumin (Transthyretin, referred to as TTR), also known as transthyretin, is a plasma transport protein, the main function in the human body is to transport thyroid hormone (thyroxine) and vitamin A. TTR is produced by the liver, eyes, and choroid plexus, and is mainly found in cerebrospinal fluid and plasma. Among them, the content in human plasma is about 0.2 mg / mL.

[0003] TTR was first isolated and sequenced from plasma by D. Goodman. It is a tetrameric protein with a molecular weight of 62Kda and each monomer consists of 127 amino acid residues. The TTR monomer is composed of two β-sheets (β-sheet) inside and outside, each β-sheet contains four β-sheet strands (β-strands), and there is a stretch of 9 amino ac...

Examples

Embodiment Construction

[0018] The technical scheme of the present invention is described below with specific examples, but protection scope of the present invention is not limited thereto:

[0019] 1. Determine the PDB data of TTR protein molecules

[0020] Obtain the PDB files (PDB numbers 2QGB, 2OGC, 2OGD, 2OGE) of TTR protein molecules from the RSCB PDB database (http: / / www.rcsb.org / ), use the Sybyl-X1.2 software of Tripos Company (http: / / tripos.com / ) to preprocess it.

[0021] 2. Optimize inhibitor molecule and build 3D-QSAR model

[0022] Gaussian09 software (http: / / www.gaussian.com / ) was used to optimize the inhibitor molecule, and the optimized structure was imported into the Sybyl-X1.2 software package, and the template skeleton alignment method was used for molecular alignment. We use the starch fibrillation rate data determined by the Kelly group (Johnson, S.M.et al.J.Med.Chem.2008, 51(2):260-270), and take 1g (100-F.F.) to represent its inhibition of starch fibrillation Ability to act...